Intralymfatisk allergenspecifik immunterapi

TY - JOUR

T1 - Intralymfatisk allergenspecifik immunterapi

AU - Næraa, Sara Haunstrup

AU - Schollert, Niels-Erik Harbo

AU - Flader Skov, Peter Nytofte

AU - Homøe, Preben

PY - 2018/5/28

Y1 - 2018/5/28

N2 - An emerging method for allergen-specific immunotherapy is intralymphatic placement, which only requires three injections with intervals of four weeks. In this review, we summarise available evidence on clinical safety, biological efficacy and therapeutic outcomes. The treatment appears to be safe with only few and mild adverse reactions. The immunological activation profile is comparable to that known for subcutaneous therapy. Clinically, patients experienced fewer symptoms with less medication use with intralymphatic allergen-specific immunotherapy than with other types of immunotherapy. The number of studies is limited, and the studies have important limitations. More phase 3 studies are needed in order to make a conclusion.

AB - An emerging method for allergen-specific immunotherapy is intralymphatic placement, which only requires three injections with intervals of four weeks. In this review, we summarise available evidence on clinical safety, biological efficacy and therapeutic outcomes. The treatment appears to be safe with only few and mild adverse reactions. The immunological activation profile is comparable to that known for subcutaneous therapy. Clinically, patients experienced fewer symptoms with less medication use with intralymphatic allergen-specific immunotherapy than with other types of immunotherapy. The number of studies is limited, and the studies have important limitations. More phase 3 studies are needed in order to make a conclusion.

M3 - Tidsskriftartikel

C2 - 29808813

SN - 0041-5782

VL - 180

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 22

M1 - V09170695

ER -